According to this study, the global Antibody Drug Conjugate CDMO market size will reach US$ 7354 million by 2031.

Antibody-Drug Conjugate (ADC) is a type of targeted cancer therapy that utilizes monoclonal antibodies to deliver cytotoxic drugs directly to cancer cells, minimizing damage to healthy cells. ADCs have shown promising results in treating various types of cancers.A Contract Development and Manufacturing Organization (CDMO) specializes in providing services related to the development, manufacturing, and testing of pharmaceuticals, including biologics like ADCs.

Antibody Drug Conjugates (ADCs) represent one of the fastest-growing and most sophisticated segments in targeted cancer therapy. By combining the precise targeting ability of monoclonal antibodies with the potent cell-killing effect of cytotoxic drugs, ADCs offer a powerful treatment strategy that minimizes harm to healthy tissues.

However, ADCs are among the most complex biologic-drug hybrids to manufacture — they require expertise in biologics production, high-potency active pharmaceutical ingredient (HPAPI) synthesis, advanced conjugation technology, and high-containment fill-finish capabilities.

This is where Contract Development and Manufacturing Organizations (CDMOs) come in. They provide specialized technical infrastructure and know-how for biopharma companies that want to develop and commercialize ADCs without building expensive in-house capacity.

The ADC CDMO market has grown significantly in recent years, fueled by an expanding pipeline of ADCs in clinical trials and rising numbers of commercial approvals. Leading CDMOs now offer end-to-end solutions covering monoclonal antibody production, payload synthesis, conjugation, and sterile, high-containment packaging.

Growing Number of Approved ADCs and Robust Clinical Pipeline

More than a dozen ADCs have received regulatory approval worldwide, with blockbusters like Enhertu®, Padcev®, and Polivy® demonstrating strong commercial success. At the same time, hundreds of new ADCs are in preclinical and clinical development targeting a wide range of cancers and even some non-oncology indications. This expanding pipeline fuels sustained demand for expert CDMO services from early development through to commercial scale-up.

Rising Demand for End-to-End Solutions

Pharma companies increasingly prefer one-stop CDMO partners that can handle the entire ADC value chain — from cell line development to final fill-finish — under a single quality system and contract. This integrated model simplifies supply chains, shortens development timelines, and reduces risk, giving CDMOs with full-spectrum ADC capabilities a competitive edge.

    Increased Investment in High-Potency Manufacturing Capacity

As the ADC market expands, leading CDMOs are investing heavily to expand or build new high-containment suites and HPAPI production lines. This growth is critical because HPAPI synthesis and handling require specialized equipment, isolated work areas, and rigorous operator safety systems.

Companies like Lonza, WuXi XDC, Piramal Pharma Solutions, and Sterling Pharma Solutions have made significant capital investments to meet the increasing global demand.

LPI (LP Information)' newest research report, the “Antibody Drug Conjugate CDMO Industry Forecast” looks at past sales and reviews total world Antibody Drug Conjugate CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Antibody Drug Conjugate CDMO sales for 2025 through 2031. With Antibody Drug Conjugate CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody Drug Conjugate CDMO industry.

This Insight Report provides a comprehensive analysis of the global Antibody Drug Conjugate CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody Drug Conjugate CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody Drug Conjugate CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody Drug Conjugate CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody Drug Conjugate CDMO.

This report presents a comprehensive overview, market shares, and growth opportunities of Antibody Drug Conjugate CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Cleavable Linker ADCs

    Non-Cleavable Linker ADCs

Segmentation by Application:

    Small and Medium-sized Pharmaceutical Companies

    Large Pharmaceutical Companies

This report also splits the market by region:

    Americas

    United States

    Canada

    Mexico

    Brazil

    APAC

    China

    Japan

    Korea

    Southeast Asia

    India

    Australia

    Europe

    Germany

    France

    UK

    Italy

    Russia

    Middle East & Africa

    Egypt

    South Africa

    Israel

    Turkey

    GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

    Lonza Group

    Porton Pharma Solutions

    WuXi XDC

    BOC Sciences

    Asymchem

    Catalent Biologics

    3PBIOVIAN

    Genscript

    AGC Biologics

    MabPlex

    ChemExpress

    Abzena

    Ajinomoto Bio-Pharma Services

    BSP Pharmaceuticals

    AbbVie Contract Manufacturing

    TOT Biopharm

    Huadong Medicine

    Innovent Biologics

    Zhenhao Biology

    Porton Pharma Solutions

1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
    1.8 Market Estimation Caveats

2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Antibody Drug Conjugate CDMO Market Size (2020-2031)
        2.1.2 Antibody Drug Conjugate CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031)
        2.1.3 World Current & Future Analysis for Antibody Drug Conjugate CDMO by Country/Region (2020, 2024 & 2031)
    2.2 Antibody Drug Conjugate CDMO Segment by Type
        2.2.1 Cleavable Linker ADCs
        2.2.2 Non-Cleavable Linker ADCs
    2.3 Antibody Drug Conjugate CDMO Market Size by Type
        2.3.1 Antibody Drug Conjugate CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031)
        2.3.2 Global Antibody Drug Conjugate CDMO Market Size Market Share by Type (2020-2025)
    2.4 Antibody Drug Conjugate CDMO Segment by Application
        2.4.1 Small and Medium-sized Pharmaceutical Companies
        2.4.2 Large Pharmaceutical Companies
    2.5 Antibody Drug Conjugate CDMO Market Size by Application
        2.5.1 Antibody Drug Conjugate CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031)
        2.5.2 Global Antibody Drug Conjugate CDMO Market Size Market Share by Application (2020-2025)

3 Antibody Drug Conjugate CDMO Market Size by Player
    3.1 Antibody Drug Conjugate CDMO Market Size Market Share by Player
        3.1.1 Global Antibody Drug Conjugate CDMO Revenue by Player (2020-2025)
        3.1.2 Global Antibody Drug Conjugate CDMO Revenue Market Share by Player (2020-2025)
    3.2 Global Antibody Drug Conjugate CDMO Key Players Head office and Products Offered
    3.3 Market Concentration Rate Analysis
        3.3.1 Competition Landscape Analysis
        3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
    3.4 New Products and Potential Entrants
    3.5 Mergers & Acquisitions, Expansion

4 Antibody Drug Conjugate CDMO by Region
    4.1 Antibody Drug Conjugate CDMO Market Size by Region (2020-2025)
    4.2 Global Antibody Drug Conjugate CDMO Annual Revenue by Country/Region (2020-2025)
    4.3 Americas Antibody Drug Conjugate CDMO Market Size Growth (2020-2025)
    4.4 APAC Antibody Drug Conjugate CDMO Market Size Growth (2020-2025)
    4.5 Europe Antibody Drug Conjugate CDMO Market Size Growth (2020-2025)
    4.6 Middle East & Africa Antibody Drug Conjugate CDMO Market Size Growth (2020-2025)

5 Americas
    5.1 Americas Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)
    5.2 Americas Antibody Drug Conjugate CDMO Market Size by Type (2020-2025)
    5.3 Americas Antibody Drug Conjugate CDMO Market Size by Application (2020-2025)
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil

6 APAC
    6.1 APAC Antibody Drug Conjugate CDMO Market Size by Region (2020-2025)
    6.2 APAC Antibody Drug Conjugate CDMO Market Size by Type (2020-2025)
    6.3 APAC Antibody Drug Conjugate CDMO Market Size by Application (2020-2025)
    6.4 China
    6.5 Japan
    6.6 South Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia

7 Europe
    7.1 Europe Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)
    7.2 Europe Antibody Drug Conjugate CDMO Market Size by Type (2020-2025)
    7.3 Europe Antibody Drug Conjugate CDMO Market Size by Application (2020-2025)
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia

8 Middle East & Africa
    8.1 Middle East & Africa Antibody Drug Conjugate CDMO by Region (2020-2025)
    8.2 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Type (2020-2025)
    8.3 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Application (2020-2025)
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries

9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends

10 Global Antibody Drug Conjugate CDMO Market Forecast
    10.1 Global Antibody Drug Conjugate CDMO Forecast by Region (2026-2031)
        10.1.1 Global Antibody Drug Conjugate CDMO Forecast by Region (2026-2031)
        10.1.2 Americas Antibody Drug Conjugate CDMO Forecast
        10.1.3 APAC Antibody Drug Conjugate CDMO Forecast
        10.1.4 Europe Antibody Drug Conjugate CDMO Forecast
        10.1.5 Middle East & Africa Antibody Drug Conjugate CDMO Forecast
    10.2 Americas Antibody Drug Conjugate CDMO Forecast by Country (2026-2031)
        10.2.1 United States Market Antibody Drug Conjugate CDMO Forecast
        10.2.2 Canada Market Antibody Drug Conjugate CDMO Forecast
        10.2.3 Mexico Market Antibody Drug Conjugate CDMO Forecast
        10.2.4 Brazil Market Antibody Drug Conjugate CDMO Forecast
    10.3 APAC Antibody Drug Conjugate CDMO Forecast by Region (2026-2031)
        10.3.1 China Antibody Drug Conjugate CDMO Market Forecast
        10.3.2 Japan Market Antibody Drug Conjugate CDMO Forecast
        10.3.3 Korea Market Antibody Drug Conjugate CDMO Forecast
        10.3.4 Southeast Asia Market Antibody Drug Conjugate CDMO Forecast
        10.3.5 India Market Antibody Drug Conjugate CDMO Forecast
        10.3.6 Australia Market Antibody Drug Conjugate CDMO Forecast
    10.4 Europe Antibody Drug Conjugate CDMO Forecast by Country (2026-2031)
        10.4.1 Germany Market Antibody Drug Conjugate CDMO Forecast
        10.4.2 France Market Antibody Drug Conjugate CDMO Forecast
        10.4.3 UK Market Antibody Drug Conjugate CDMO Forecast
        10.4.4 Italy Market Antibody Drug Conjugate CDMO Forecast
        10.4.5 Russia Market Antibody Drug Conjugate CDMO Forecast
    10.5 Middle East & Africa Antibody Drug Conjugate CDMO Forecast by Region (2026-2031)
        10.5.1 Egypt Market Antibody Drug Conjugate CDMO Forecast
        10.5.2 South Africa Market Antibody Drug Conjugate CDMO Forecast
        10.5.3 Israel Market Antibody Drug Conjugate CDMO Forecast
        10.5.4 Turkey Market Antibody Drug Conjugate CDMO Forecast
    10.6 Global Antibody Drug Conjugate CDMO Forecast by Type (2026-2031)
    10.7 Global Antibody Drug Conjugate CDMO Forecast by Application (2026-2031)
        10.7.1 GCC Countries Market Antibody Drug Conjugate CDMO Forecast

11 Key Players Analysis
    11.1 Lonza Group
        11.1.1 Lonza Group Company Information
        11.1.2 Lonza Group Antibody Drug Conjugate CDMO Product Offered
        11.1.3 Lonza Group Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.1.4 Lonza Group Main Business Overview
        11.1.5 Lonza Group Latest Developments
    11.2 Porton Pharma Solutions
        11.2.1 Porton Pharma Solutions Company Information
        11.2.2 Porton Pharma Solutions Antibody Drug Conjugate CDMO Product Offered
        11.2.3 Porton Pharma Solutions Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.2.4 Porton Pharma Solutions Main Business Overview
        11.2.5 Porton Pharma Solutions Latest Developments
    11.3 WuXi XDC
        11.3.1 WuXi XDC Company Information
        11.3.2 WuXi XDC Antibody Drug Conjugate CDMO Product Offered
        11.3.3 WuXi XDC Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.3.4 WuXi XDC Main Business Overview
        11.3.5 WuXi XDC Latest Developments
    11.4 BOC Sciences
        11.4.1 BOC Sciences Company Information
        11.4.2 BOC Sciences Antibody Drug Conjugate CDMO Product Offered
        11.4.3 BOC Sciences Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.4.4 BOC Sciences Main Business Overview
        11.4.5 BOC Sciences Latest Developments
    11.5 Asymchem
        11.5.1 Asymchem Company Information
        11.5.2 Asymchem Antibody Drug Conjugate CDMO Product Offered
        11.5.3 Asymchem Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.5.4 Asymchem Main Business Overview
        11.5.5 Asymchem Latest Developments
    11.6 Catalent Biologics
        11.6.1 Catalent Biologics Company Information
        11.6.2 Catalent Biologics Antibody Drug Conjugate CDMO Product Offered
        11.6.3 Catalent Biologics Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.6.4 Catalent Biologics Main Business Overview
        11.6.5 Catalent Biologics Latest Developments
    11.7 3PBIOVIAN
        11.7.1 3PBIOVIAN Company Information
        11.7.2 3PBIOVIAN Antibody Drug Conjugate CDMO Product Offered
        11.7.3 3PBIOVIAN Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.7.4 3PBIOVIAN Main Business Overview
        11.7.5 3PBIOVIAN Latest Developments
    11.8 Genscript
        11.8.1 Genscript Company Information
        11.8.2 Genscript Antibody Drug Conjugate CDMO Product Offered
        11.8.3 Genscript Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.8.4 Genscript Main Business Overview
        11.8.5 Genscript Latest Developments
    11.9 AGC Biologics
        11.9.1 AGC Biologics Company Information
        11.9.2 AGC Biologics Antibody Drug Conjugate CDMO Product Offered
        11.9.3 AGC Biologics Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.9.4 AGC Biologics Main Business Overview
        11.9.5 AGC Biologics Latest Developments
    11.10 MabPlex
        11.10.1 MabPlex Company Information
        11.10.2 MabPlex Antibody Drug Conjugate CDMO Product Offered
        11.10.3 MabPlex Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.10.4 MabPlex Main Business Overview
        11.10.5 MabPlex Latest Developments
    11.11 ChemExpress
        11.11.1 ChemExpress Company Information
        11.11.2 ChemExpress Antibody Drug Conjugate CDMO Product Offered
        11.11.3 ChemExpress Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.11.4 ChemExpress Main Business Overview
        11.11.5 ChemExpress Latest Developments
    11.12 Abzena
        11.12.1 Abzena Company Information
        11.12.2 Abzena Antibody Drug Conjugate CDMO Product Offered
        11.12.3 Abzena Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.12.4 Abzena Main Business Overview
        11.12.5 Abzena Latest Developments
    11.13 Ajinomoto Bio-Pharma Services
        11.13.1 Ajinomoto Bio-Pharma Services Company Information
        11.13.2 Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Product Offered
        11.13.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.13.4 Ajinomoto Bio-Pharma Services Main Business Overview
        11.13.5 Ajinomoto Bio-Pharma Services Latest Developments
    11.14 BSP Pharmaceuticals
        11.14.1 BSP Pharmaceuticals Company Information
        11.14.2 BSP Pharmaceuticals Antibody Drug Conjugate CDMO Product Offered
        11.14.3 BSP Pharmaceuticals Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.14.4 BSP Pharmaceuticals Main Business Overview
        11.14.5 BSP Pharmaceuticals Latest Developments
    11.15 AbbVie Contract Manufacturing
        11.15.1 AbbVie Contract Manufacturing Company Information
        11.15.2 AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Product Offered
        11.15.3 AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.15.4 AbbVie Contract Manufacturing Main Business Overview
        11.15.5 AbbVie Contract Manufacturing Latest Developments
    11.16 TOT Biopharm
        11.16.1 TOT Biopharm Company Information
        11.16.2 TOT Biopharm Antibody Drug Conjugate CDMO Product Offered
        11.16.3 TOT Biopharm Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.16.4 TOT Biopharm Main Business Overview
        11.16.5 TOT Biopharm Latest Developments
    11.17 Huadong Medicine
        11.17.1 Huadong Medicine Company Information
        11.17.2 Huadong Medicine Antibody Drug Conjugate CDMO Product Offered
        11.17.3 Huadong Medicine Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.17.4 Huadong Medicine Main Business Overview
        11.17.5 Huadong Medicine Latest Developments
    11.18 Innovent Biologics
        11.18.1 Innovent Biologics Company Information
        11.18.2 Innovent Biologics Antibody Drug Conjugate CDMO Product Offered
        11.18.3 Innovent Biologics Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.18.4 Innovent Biologics Main Business Overview
        11.18.5 Innovent Biologics Latest Developments
    11.19 Zhenhao Biology
        11.19.1 Zhenhao Biology Company Information
        11.19.2 Zhenhao Biology Antibody Drug Conjugate CDMO Product Offered
        11.19.3 Zhenhao Biology Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.19.4 Zhenhao Biology Main Business Overview
        11.19.5 Zhenhao Biology Latest Developments
    11.20 Porton Pharma Solutions
        11.20.1 Porton Pharma Solutions Company Information
        11.20.2 Porton Pharma Solutions Antibody Drug Conjugate CDMO Product Offered
        11.20.3 Porton Pharma Solutions Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)
        11.20.4 Porton Pharma Solutions Main Business Overview
        11.20.5 Porton Pharma Solutions Latest Developments

12 Research Findings and Conclusion